Pricing Log in Create free account
Saturday 17 October 2026 Export PBYI’s income statement to Excel — free account

Puma Biotechnology, Inc.

PBYI Healthcare Biotechnology

Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024. In the quarter to June 2026, revenue grew 7.75%, EPS grew 33.3%, free cash flow fell 88.5% and total debt fell 79.8%, each against the same quarter a year earlier. Operating cash flow growth for three consecutive years.

9.83 0.69 −6.56%
Market cap
$543.0M
P/E
18.2×
Fwd P/E
24.2×
Dividend yield
—
F-score
8/9
Altman Z
−4.16
Beneish M
−2.06
Dividend safety
n/a
Overview Business Profile Financial Analysis Income Statement Balance Sheet Cash Flow Metrics & Ratios 10-Q 10-K

Insider Decisions trades per month

Total sells 2.12
Totals in millions of $.
Dec 25 Mar 26 Jun 26 Sep 26
Buy — — — — — — — — — — — —
Sell 1 — 3 — — — — 5 3 — 2 —
Insider Ownership 21.32%

Capital & Financial Ratios $m

Market Cap 543.04
Revenue 231.24
Net Income 26.72
Free Cash Flow 41.15
Net Debt (93.90)
Current Ratio 2.91 (at or above 1.5: strong)
Debt/Equity 0.00 (at or below 0.5: strong)
P/E ratio 18.20
Fwd P/E 24.20
P/S ratio 2.17
P/B ratio 3.61
Past 5Y EPS Growth —
This Y EPS Growth (37.70%) (below 0%: weak)
Next Y EPS Growth (47.37%) (below 0%: weak)
Next Y revenue growth (1.04%) (below 0%: weak)
Next 5Y EPS Growth (9.64%) (below 0%: weak)

Green and red mark values outside typical ranges. How we judge →

Valuation vs history

EV/Sales, ten years
EV/Sales is 1.9×, against a ten-year median of 1.0×; over the ten years it ranged from 0.4× in 2022 to 12.5× in 2018.
P/E against its own 10 years 74.45%
10-year low 10-year high
P/S against its own 10 years 88.44%
10-year low 10-year high
P/B against its own 10 years 24.41%
10-year low 10-year high
EV/Sales against its own 10 years 84.56%
10-year low 10-year high
EV/FCF against its own 10 years 67.97%
10-year low 10-year high

Dividends

Payout Ratio —
Annual Dividend Rate —
Annual Dividend Yield —
total individual payouts
2025 Powerpack
2024 Powerpack
2023 Powerpack
2022 Powerpack
2021 Powerpack
2020 Powerpack
2019 Powerpack
2017 Powerpack
predictions special payouts not included in total or ratios

Assets vs Liabilities $m

2023 2024 2025 Q'26
Cash 96 101 100 94
Receivables 48 32 54 34
Inventory 7 9 6 13
Other 1 0 0 0
156 148 163 145
2023 2024 2025 Q'26
Payables 7 6 5 3
ST’ Debt 34 45 23 —
Other 1 3 2 1
99 96 81 50

Compound Annual Growth %

10y 5y 3y
Sales — 0.29% 0.05%
Cash Flow 0.00% 122.13% 0.00%
Earnings 0.00% 0.00% 2,396.29%
Book Value (4.47%) 0.00% 82.03%

Revenue $m

Mar Jun Sep Dec Year
’26 45 57 — — —
’25 46 52 54 75 228
’24 44 47 81 59 230
’23 53 55 56 72 236
’22 46 60 57 66 228
’21 98 53 46 55 253
’20 51 71 51 53 225
Fiscal quarters ending in the months shown.

Operating Cash Flow $m

Mar Jun Sep Dec Year
’26 15 2 — — —
’25 4 14 10 14 42
’24 11 1 11 16 39
’23 3 3 11 10 27
’22 (27) (14) 17 8 (16)
’21 16 0 10 (5) 21
’20 (12) 16 2 (6) 1
Fiscal quarters ending in the months shown.

Free Cash Flow $m

Mar Jun Sep Dec Year
’26 15 2 — — —
’25 4 14 10 14 42
’24 11 1 11 16 39
’23 (10) 3 11 10 14
’22 (27) (14) 17 1 (23)
’21 16 0 10 (5) 21
’20 (12) 6 2 (6) (9)
Fiscal quarters ending in the months shown.

EPS $

Mar Jun Sep Dec Year
’26 (0.07) 0.16 — — —
’25 0.06 0.12 0.17 0.26 0.61
’24 (0.10) (0.09) 0.41 0.39 0.62
’23 0.03 0.05 0.12 0.26 0.45
’22 (0.08) 0.21 (0.01) (0.12) 0.00
’21 0.40 (0.13) (1.09) 0.10 (0.72)
’20 (0.43) 0.08 (0.79) (0.38) (1.52)
Fiscal quarters ending in the months shown.

Target Price Range

Analyst price targets

Recommendation Rating

3
1Buy 2 3Hold 4 5Sell

Ten years at a glance Fiscal years to December

Group Line 2016 2017 2018 2019 2020 2021 2022 2023 2024 2025 Trend 2026e 2027e 2028e
Price, $
Price, $ Low 19.74 28.35 17.60 6.26 5.50 2.78 1.60 2.13 2.23 2.58

Analyst estimates 2026–2028

Powerpack
High 77.99 136.90 101.50 43.90 15.00 14.14 5.16 4.89 7.73 6.27
People
People Employees 160 318 272 269 267 196 192 185 172 179
Revenue/emp, $m 0.00 0.09 0.92 1.01 0.84 1.29 1.19 1.27 1.34 1.28
Income, $m
Income, $m Revenue — 28 251 272 225 253 228 236 230 228
Gross margin, % 0.00 79.87 86.21 86.48 82.51 74.84 75.84 73.40 72.06 74.53
EBT (276) (292) (114) (76) (60) (29) 0 23 24 36
EBT margin, % 0.00 (1,054.56) (45.24) (27.75) (26.56) (11.38) 0.20 9.62 10.46 15.67
Net income (276) (292) (114) (76) (60) (29) 0 22 30 31
Depreciation 1 3 7 8 10 11 10 12 12 11
Per share, $
Per share, $ Revenue 0.00 0.74 6.62 7.02 5.69 6.23 5.10 5.00 4.74 4.57
Earnings (8.29) (7.85) (2.99) (1.95) (1.52) (0.72) 0.00 0.46 0.62 0.62
Cash flow (4.26) (4.64) (0.64) 0.58 0.02 0.51 (0.35) 0.57 0.80 0.84
Capex (0.22) (1.36) (0.02) (0.01) (0.25) 0.00 (0.16) (0.27) 0.00 0.00
Free cash flow (4.47) (6.00) (0.65) 0.57 (0.23) 0.51 (0.51) 0.30 0.80 0.83
Book value 6.30 1.43 0.90 0.45 (0.15) (0.06) 0.48 1.13 1.89 2.61
Shares, m 33 37 38 39 40 41 45 47 49 50
Valuation, ×
Valuation, × P/E — 0.00 0.00 0.00 0.00 0.00 1,966.67 9.85 5.00 9.44
P/S — 0.00 3.08 1.25 1.80 0.49 0.81 0.91 0.64 1.30
P/B — 64.61 22.51 19.43 0.00 0.00 8.54 4.00 1.61 2.28
EV/Sales — 0.00 3.02 1.16 1.79 0.53 0.90 0.92 0.50 1.01
EV/FCF — (19.73) (30.69) 14.71 (41.98) 12.94 (8.88) 15.14 4.35 7.91
Cash, $m
Cash, $m Operating cash flow (142) (172) (24) 22 1 21 (16) 27 39 42
Capex (7) (50) (1) 0 (10) — (7) (13) 0 0
Free cash flow (149) (223) (25) 22 (9) 21 (23) 14 39 42
Balance, $m
Balance, $m Working capital 199 48 136 75 32 30 57 57 52 81
Total debt — 48 152 98 98 101 102 100 67 23
Net debt (229) (33) (14) (23) (4) 10 21 4 (34) (77)
Shareholders’ equity 210 53 34 17 (6) (2) 22 53 92 130
Returns, %
Returns, % ROA (112.06) (139.59) (53.49) (30.60) (25.04) (12.37) 0.00 9.54 13.64 14.48
ROIC 0.00 (910.03) (284.82) 0.00 0.00 11.10 34.49 35.69 33.25 43.78
ROE (132.75) (221.91) (259.28) (292.05) (1,042.29) 693.73 0.02 57.54 41.60 27.97
Negative figures in brackets.

All 10 years →

Fiscal years to Dec 2025 · latest quarter Jun 2026

Charts ten years each

Puma Biotechnology, Inc. vs peers in Biotechnology (Q) = latest quarter vs a year earlier

Company Market cap P/E Fwd P/E Revenue growth (Q) EPS growth (Q) FCF growth (Q) Gross margin (Q) EBIT margin (Q) Compare
DBVT DBV Technologies S.A. $572.6M — (loss-making) — −53.33% (below 0%: shrinking) n/m −56.15% (below 0%: shrinking) 100.00% (7,228.57%) Compare
VALN Valneva SE Sponsored ADR $560.4M 59.7× 19.4× −17.29% (below 0%: shrinking) n/m −56.05% (below 0%: shrinking) 15.29% (76.67%) Compare
STTK Shattuck Labs, Inc. $555.0M — (loss-making) — (loss-making) −10.31% (below 0%: shrinking) n/m +1.01% (above 0%: growing) 100.00% 0.00% Compare
VECT VectivBio Holding AG $545.5M — (loss-making) — (loss-making) — n/m — 91.93% 0.00% Compare
PBYI Puma Biotechnology, Inc. $543.0M 18.2× 24.2× +7.75% (above 0%: growing) +33.33% (above 0%: growing) −88.45% (below 0%: shrinking) 77.92% 13.42%
DRUG Bright Minds Biosciences Inc. $534.7M — (loss-making) — — n/m −124.63% (below 0%: shrinking) 0.00% 0.00% Compare
FTH Faeth Therapeutics, Inc. $532.3M — (loss-making) — — n/m −174.24% (below 0%: shrinking) 0.00% 0.00% Compare
CTMX CytomX Therapeutics, Inc. $525.1M — (loss-making) — (loss-making) −92.40% (below 0%: shrinking) n/m −14.50% (below 0%: shrinking) 100.00% (1,677.08%) Compare
CYVNY Ceryvyn Therapeutics Ltd. - Unsponsored ADR $524.8M — (loss-making) — (loss-making) −7.53% (below 0%: shrinking) n/m −31.52% (below 0%: shrinking) 0.00% 0.00% Compare
Median of peers $540.1M — — −17.29% — −56.05% 53.61% 0.00%

All 614 Biotechnology stocks →

Puma Biotechnology, Inc. (PBYI) key facts

  • Concern: Puma Biotechnology, Inc.’s revenue for fiscal 2025 (year ended December 2025) was $228.4 million, down 0.91% from fiscal 2024.
  • Puma Biotechnology, Inc. (PBYI) is a Biotechnology company in the Healthcare sector, listed on Nasdaq.
  • As of October 16, 2026, PBYI traded at $9.83, a market capitalization of $543.0 million.
  • Return on equity was 28.0% and debt-to-equity 0.00.
  • Its Piotroski F-score is 8 out of 9 and its Altman Z-score is −4.16 (distress zone) for fiscal 2025.

Source: company filings (standardised) and stockrow calculations.

Puma Biotechnology, Inc. (PBYI) Latest News

No news at this impact. Lower the threshold for more.
stockrow.com/PBYI · Data as of Jun 30, 2026 · For information only; not investment advice. · © 2026 stockrow.com